Pacific Biosciences of California, Inc. (PACB) company profile
Close on Nov 16, 2026Market cap $571.93MP/E –Yield 0.00%
About Pacific Biosciences of California
Laboratory Analytical Instruments, SIC 3826
PacBio designs, manufactures, and sells genomic sequencing systems, microchips, and reagents built on its proprietary Single-Molecule Real-Time sequencing technology. Its products, which include Revio, Vega, and Sequel instruments alongside SMRT Cells and specialized assay kits, enable high-accuracy long-read sequencing of DNA and RNA. Researchers deploy these tools across rare disease research, human germline analysis, oncology, infectious disease surveillance, and plant and animal biology. The company supplies academic and governmental institutions, commercial laboratories, clinical research facilities, hospitals, agricultural enterprises, and biopharmaceutical organizations.
The company operates a primary manufacturing and service facility in Menlo Park, California, supported by domestic and international contract manufacturers. It markets and distributes its sequencing platforms worldwide through a direct sales organization alongside distribution partners across Europe, Australia, parts of Asia, the Middle East, Africa, Central America, and South America.
Summary of the business section of Pacific Biosciences of California's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pacific Biosciences of California, Inc.
- Founded
- 2004
- Headquarters
- Menlo Park, CA
- Address
- 1305 O'Brien Drive 94025
- Phone
- (650) 521-8000
- Website
- www.pacb.com
- Employees
- 485, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- PACB
- Exchange
- Nasdaq
- IPO date
- Oct 27, 2010
- Shares outstanding
- 311M, Jul 31, 2026
- Public float
- $369.90M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1299130
- CUSIP
- 69404D108
- ISIN
- US69404D1081
- FIGI
- BBG000QKXH20
- Share class FIGI
- BBG001SS9G64
- LEI
- 529900F1BWRE1M0KZN89
- EIN
- 16-1590339
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Meyer | See Remarks | 44,000 |
| James R. Gibson II | See Remarks | 1,083,848 |
| Oene Mark Van | See Remarks | 2,705,853 |
| Michele Farmer | See Remarks | 305,948 |
| Christian O. Henry | See Remarks | 3,581,813 |
| Randall S. Livingston | Director | 22,821 |
| William W. Ericson | Director | 4,890,013 |
| Kathy Ordonez | Director | 403,037 |
| Christopher Gibson | Director | 111,386 |
| Christopher M. Smith | Director | 54,099 |
| Marshall Mohr | Director | 132,821 |
| John F. Milligan | Director | 132,821 |
| Hannah Valantine | Director | 22,821 |
| Lucy Shapiro | Director | 22,821 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.31M | $5.53M | $2.93M | $7 | $125 |
| FY2024 | $9.18M | -$5.98M | $3.60M | $7 | $93 |
| FY2023 | $8.05M | $10.05M | $3.22M | $38 | $94 |
| FY2022 | $6.62M | -$13.14M | $4.47M | $32 | $90 |
| FY2021 | $2.87M | -$6.45M | $11.10M | $79 | $100 |
| FY2020 | $12.48M | $51.60M | $1.86M | $505 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Christian O. Henry President and Chief Executive Officer | $748.25K | $1.15M | $1.70M | $714.31K | $4.31M | -53% |
| Jim R. Gibson Chief Financial Officer | $376.92K | $1.18M | $1.74M | $198.07K | $3.49M | – |
| Mark Van Oene Chief Operating Officer | $620.13K | $561.47K | $827.45K | $357.07K | $2.37M | -51% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 485 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 2, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 20, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 18, 2018 | Merger vote | Definitive merger proxy statement |
| Jun 21, 2011 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 6, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 28, 2004 | Name change | Name changed from NANOFLUIDICS INC to PACIFIC BIOSCIENCES OF CALIFORNIA INC |
See a number that looks wrong?